RxSight Light Adjustable Lens and Light Delivery Device
Rxsight, Inc. · Decision date Sep 3, 2026
What did the FDA approve?
The FDA record lists P160055/S056 as an approval dated 2026-09-03 for Rxsight, Inc., under product code PZK in the ophthalmic specialty. The supplement type is Real-Time Process, with the reason given as Change Design/Components/Specifications/Material. Because the identifier ties S056 to PMA P160055, the decision amends that existing approval rather than approving the RxSight Light Adjustable Lens and Light Delivery Device system anew.
The supplied statement covers updates to Light Delivery Device Model 61002-006 and Model 61002-007 software: minor graphical user interface enhancements, changes to internal manufacturing and service tools, software processing optimizations, and resolution of identified bugs. The statement does not specify which bugs, what the GUI changes alter, or how the optimizations affect device function, so those details remain unknown, and the record itself does not establish safety or clinical effectiveness.
FDA approval order statement
Approval for updates to the Light Delivery Device (LDD) Model 61002-006 software and Model 61002-007 software that include minor enhancements to the graphical user interface (GUI), improvements to internal manufacturing and service tools, software processing optimizations, and resolution of identified bugs
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Ophthalmic
- Decision date
- Sep 3, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P160055/S056
- Regulatory pathway
- PMA supplement
- Applicant
- Rxsight, Inc.
- Product code
- PZK
- Decision code
- APPR
- Decision date
- Sep 3, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Light adjustable lens (LAL) and light delivery device (LDD).
- Applicant
- Rxsight, Inc.
- Product code
- PZK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P160055. Subsequent supplements may change the device or its indications.
FDA decision timeline
P160055 · Original PMA
LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)
P160055/S056 received
Application receipt date recorded by FDA.
P160055/S056 · FDA decision
Real-Time Process
P160055/S058 · Related supplement
RxSight Light Adjustable Lens and Light Delivery Device
P160055/S057 · Related supplement
RxSight Light Adjustable Lens and Light Delivery Device
Timeline entries are records held by MedtechLedger for P160055. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160055
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Rxsight, Inc. | PMA approval | Nov 22, 2017 | FDA | |
| Rxsight, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
| Rxsight, Inc. | PMA supplement | Nov 5, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Rxsight, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 100 Columbia, Aliso Viejo, CA, 92656
Sources and methodology
- Original FDA record: P160055/S056
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

